Virpax Pharmaceuticals, Inc.
VRPX
$0.30
$0.04417.19%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.24% | -83.09% | -22.91% | 1.42% | 1,503.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.53% | -68.53% | 6.76% | 13.84% | 325.02% |
| Operating Income | 27.53% | 68.53% | -6.76% | -13.84% | -325.02% |
| Income Before Tax | 25.68% | 66.53% | -10.84% | -111.80% | -52.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.68% | 66.53% | -10.84% | -111.80% | -52.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.68% | 66.53% | -10.84% | -111.80% | -52.71% |
| EBIT | 27.53% | 68.53% | -6.76% | -13.84% | -325.02% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 90.57% | 91.58% | 34.34% | -111.80% | -52.63% |
| Normalized Basic EPS | 90.57% | 91.58% | 34.34% | -16.24% | -361.90% |
| EPS Diluted | 90.57% | 91.58% | 34.34% | -111.80% | -52.63% |
| Normalized Diluted EPS | 90.57% | 91.58% | 34.34% | -16.24% | -361.90% |
| Average Basic Shares Outstanding | 688.43% | 297.69% | 68.80% | 0.00% | 0.05% |
| Average Diluted Shares Outstanding | 688.43% | 297.69% | 68.80% | 0.00% | 0.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |